Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $45.00

Syndax Pharmaceuticals (NASDAQ:SNDX - Free Report) had its price target upped by Citigroup from $37.00 to $45.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts also recently issued reports on the company. Bank of America increased their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a "buy" rating in a report on Thursday, August 15th. UBS Group started coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a "buy" rating and a $37.00 price objective on the stock. HC Wainwright lifted their target price on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a "buy" rating in a research note on Monday. Barclays lifted their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an "overweight" rating in a report on Thursday, August 15th. Finally, StockNews.com upgraded Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.18.

Syndax Pharmaceuticals Stock Down 2.1 %

SNDX traded down $0.34 during trading hours on Tuesday, hitting $15.77. The stock had a trading volume of 1,488,735 shares, compared to its average volume of 1,150,461. The company's fifty day simple moving average is $18.82 and its 200 day simple moving average is $20.15. Syndax Pharmaceuticals has a 1 year low of $14.97 and a 1 year high of $25.34. The stock has a market cap of $1.35 billion, a PE ratio of -4.34 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the previous year, the firm earned ($0.73) EPS. As a group, equities analysts expect that Syndax Pharmaceuticals will post -3.61 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SNDX. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $27,000. Values First Advisors Inc. bought a new stake in Syndax Pharmaceuticals in the third quarter valued at about $30,000. nVerses Capital LLC bought a new stake in Syndax Pharmaceuticals in the second quarter valued at about $33,000. Quantbot Technologies LP bought a new stake in Syndax Pharmaceuticals during the third quarter worth about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock worth $58,000 after buying an additional 541 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).